180 Life Sciences Corp. Expands Patent Portfolio
PALO ALTO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has extended its patent portfolio with the recent grant of new patents to Yissum Research Development Company of the Hebrew University in both the US (19 Oct 2021, patent no US 11,149,014) and Canada (26 Oct 2021, patent no CA 2,944,837), which patents the Company has the exclusive rights to use through its license agreement with the Yissum Research Development Company of the Hebrew University.
The patents relate to a method for treating chronic pain or associated conditions/symptoms with novel compositions that include certain phenyl substituted cyclohexenyl compounds related to cannabidiol (CBD); these patents have already been issued for chronic pain across Europe and validated in 14 jurisdictions (Dec 2020), and China (Jan 2020). These compounds were also initially described in patents issued in Israel and the US in 2018 and 2019, respectively, with claims allowed for use in the treatment of obesity or an obesity associated disease or disorder, which the Company also has exclusive rights through agreements with the Yissum Research Development Company of the Hebrew University.
180 Life Sciences is developing synthetic cannabidiol analogues (SCAs), as part of one of its three preclinical programs, that are expected to be safe, non-psychoactive and formulated to improve efficacy and bioavailability for the treatment of pain and inflammation. The grant of these new patents for the treatment of chronic pain is an important advance for the SCA preclinical pipeline.
Dr. James Woody, 180 Life Sciences’ CEO stated, “Our priority indication is residual pain in patients with established rheumatoid arthritis (RA), who have not responded adequately to standard of care therapies. RA is estimated to affect 1% of the global population and anti-TNF biologics have been shown in many studies to be very effective in treating joint inflammation in 60-70% of cases. However, a significant number of patients still require an alternative to what is currently available. Working through different mechanisms to commonly used anti-inflammatory RA medications, we believe that SCAs could offer a complementary therapeutic strategy for addressing the unremitting pain that disables many patients.”
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).
This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; the availability and cost of materials required for trials; the risk that initial drug results will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; expectations with respect to future performance, growth and anticipated acquisitions; the continued listing of the Company on The NASDAQ Stock Market; expectations regarding the capitalization, resources and ownership structure of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; potential litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company’s drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. These reports and filings are available at www.sec.gov. All subsequent written and oral forward-looking statements concerning the Company, the studies described herein or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law.
Director of IR
180 Life Sciences Corp